FWG-33B
FWG-33B is an activator of TRMT112:METTL5 complex with an IC50 value of 0.47 μM. FWG-33B can be used for the research of breast carcinoma, hepatocellular carcinoma, nasopharyngeal carcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C24H25ClN2O3
- 分子量:424.92
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
FWG-33B (5 μM; 4 hours) engages ~40% of total TRMT112 and >90% of METTL5-complexed TRMT112 in HCT116TRMT112-FLAG:HA-METTL5 cells[1].
FWG-33B (0.01-50 μM; 3 hours pretreatment) stereoselectively engages TRMT112 in HCT116TRMT112-FLAG:HA-METTL5 cells with an IC50 of 1.0 μM[1].
FWG-33B (40 μM; 30 minutes) enhances the methyltransferase activity of WT-TRMT112:METTL5 (but not TRMT112C100A:METTL5) by ~2-fold with 12-nt and 60-nt rRNA substrates[1].
FWG-33B (40 μM; 30 minutes) increases the catalytic efficiency of WT-TRMT112:METTL5 by reducing the Km for rRNA substrate from 10 μM to 4.7 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
分子量 424.92
-
分子式 C24H25ClN2O3
-
SMILES
CC(NC(C=C1)=CC=C1O[C@H]2[C@H]3[C@H](CN(C(C=C)=O)C3)[C@@H](C4=CC(Cl)=CC=C4)C2)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)